EUVIMEDEUVIMED entdecken
Open Access

A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment

Lei Wang, Yong Ke, Qunye He, Pameila Paerhati, Weiliang Zhuang, Yali Yue, Junjun Liu, Jiawei Zhang, Lulu Huang, Qiang Yin, Huifang Zong, Jianwei Zhu und 1 weitere

Theranostics · 01.01.2025 · 15 (4) · 1238-1254

DOI: 10.7150/thno.102531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 01.01.2025. Verfasst von Lei Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240…. Hauptthemen laut MEDLINE: Receptor Tyrosine Kinase-like Orphan Receptors, Transcription Factors, Cell Cycle Proteins, Immunoconjugates. Die Arbeit wurde bisher 38-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor Tyrosine Kinase-like Orphan ReceptorsTranscription FactorsCell Cycle ProteinsImmunoconjugatesNeoplasmsAnimalsHumansMiceProteolysisCell Line, TumorXenograft Model Antitumor AssaysFemaleAntibodies, MonoclonalMaleBromodomain Containing Proteins

Stichwörter der Autor:innen

BRD4.Degrader-antibody conjugatePROTACTargeted protein degradationUbiquitin-proteasome system

Substanzen

Receptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanTranscription FactorsCell Cycle ProteinsBRD4 protein, humanImmunoconjugatesAntibodies, MonoclonalBromodomain Containing Proteins

Autor:innen und Institutionen

  • Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Jecho Institute, Co. Ltd, Shanghai 200240, China.

Zitieren

APA

Wang, L., Ke, Y., He, Q., Paerhati, P., Zhuang, W., Yue, Y., Liu, J., Zhang, J., Huang, L., Yin, Q., Zong, H., Zhu, J., & Zhang, B. (2025). A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment. Theranostics, 15(4), 1238-1254. https://doi.org/10.7150/thno.102531

Vancouver

Wang L, Ke Y, He Q, Paerhati P, Zhuang W, Yue Y, et al. A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment. Theranostics. 2025;15(4):1238-1254. doi:10.7150/thno.102531

BibTeX
@article{Wang2025,
  author = {Wang, Lei and Ke, Yong and He, Qunye and Paerhati, Pameila and Zhuang, Weiliang and Yue, Yali and Liu, Junjun and Zhang, Jiawei and Huang, Lulu and Yin, Qiang and Zong, Huifang and Zhu, Jianwei and Zhang, Baohong},
  title = {A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {4},
  pages = {1238--1254},
  doi = {10.7150/thno.102531}
}
Kostenlos starten →